ReEngage Therapeutics
- Company typePrivate
- Founded2024
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
ReEngage Therapeutics firmographics
Firmographics- Name
- ReEngage Therapeutics
- Website
- https://reengagetx.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Unknown
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
ReEngage Therapeutics industry classification
Industry- Product category
- Longevity Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where ReEngage Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Markets served
ReEngage Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
ReEngage Therapeutics product offering
Product offeringCore offering
ReEngage Therapeutics is a biopharmaceutical company developing drugs to treat longevity-related diseases. As an early-stage entity founded in 2024 with 1–10 employees, it is engaged in pharmaceutical research and drug development aimed at age-related conditions, though specific therapeutic candidates, modalities, and pipeline details are not disclosed in the available source material.
Differentiator
Problem solved
Functional benefit
Products and services
- Longevity-related disease therapeutics (pipeline)
Companies that use ReEngage Therapeutics
Customer profileIdeal customer profiles1 record
ReEngage Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ReEngage Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
ReEngage Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Altos Labs: Well-capitalized longevity biotech pursuing cellular rejuvenation programming. Comparable to ReEngage as a drug-development entrant in the longevity-disease category, though at vastly greater scale.
- Calico Life Sciences: Alphabet-backed longevity and aging research organization developing therapeutics for age-related diseases. Directly comparable therapeutic focus on longevity-related diseases.
Direct peers
- Unity Biotechnology: Clinical-stage biotechnology company developing senolytic therapeutics to treat age-related diseases. Closely aligned with ReEngage's stated focus on longevity-related disease treatment.
- Insilico Medicine: AI-driven biotech developing therapeutics for age-related and aging-related diseases, including longevity indications. Comparable target disease space and drug-development orientation.
- BioAge Labs: Clinical-stage biotech developing drugs that target the molecular mechanisms of aging to treat age-related diseases. Highly comparable mission and drug-development focus.
Emerging players
- Retro Biosciences: Sam Altman-backed longevity biotech developing therapeutics aimed at extending healthy human lifespan. Comparable early-stage drug-discovery orientation in the longevity category.
- NewLimit: Biotechnology company developing epigenetic reprogramming therapies to treat age-related diseases. Comparable therapeutic focus on longevity-related disease with an early-stage profile.
- Juvena Therapeutics: Preclinical-stage biotech developing protein-based therapeutics for age-related diseases and longevity. Comparable early-stage longevity therapeutics orientation.
- Gero: AI-driven longevity biotech developing therapeutics targeting aging-related diseases. Comparable longevity therapeutic focus with a data-driven discovery approach.
Regional players
- Loyal for Dogs: Veterinary-focused longevity therapeutics company developing drugs to extend dog lifespan. Comparable drug-development orientation toward longevity, but applied to veterinary rather than human indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
ReEngage Therapeutics social profiles
Digital presenceReEngage Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReEngage Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
ReEngage Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReEngage Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReEngage Therapeutics
What does ReEngage Therapeutics do?
ReEngage Therapeutics is a biopharmaceutical company developing drugs to treat longevity-related diseases. As an early-stage entity founded in 2024 with 1–10 employees, it is engaged in pharmaceutical research and drug development aimed at age-related conditions, though specific therapeutic candidates, modalities, and pipeline details are not disclosed in the available source material.
When was ReEngage Therapeutics founded?
ReEngage Therapeutics was founded in 2024. It employs 1 to 10 people.
Where is ReEngage Therapeutics based?
ReEngage Therapeutics is headquartered in Houston, United States, in the North America region.
Who are ReEngage Therapeutics's main competitors?
Broad incumbents on record are Altos Labs and Calico Life Sciences. Direct peers are Unity Biotechnology, Insilico Medicine and BioAge Labs. Emerging players are Retro Biosciences, NewLimit, Juvena Therapeutics and Gero. Loyal for Dogs is listed as a regional player.
Does ReEngage Therapeutics have an API?
No public API is recorded for ReEngage Therapeutics.
What industry is ReEngage Therapeutics in?
ReEngage Therapeutics's product category is Longevity Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2834.